MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Thursday, May 16, 2013

Research and Markets: Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.

Teva’s and Active Biotech’s laquinimod (ABR-215062) is a synthetic, once-daily, orally-administered immunomodulator under investigation for the treatment of RRMS. It is related to, but chemically distinct from, linomide (Roquinimex; Active Biotech); an experimental agent that had demonstrated some efficacy in the treatment of MS, but clinical testing was prematurely terminated because of serious cardiopulmonary toxicity.

Scope

- Overview of Multiple Sclerosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Laquinimod including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Laquinimod for the top ten countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India

source: http://www.researchandmarkets.com/research/jrn3cv/laquinimod

..



USE OUR SHARE LINKS at the top of this page  - to provide this article to others



REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register


.

No comments: